Fig. 1From: Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy resultsThe biochemical relapse-free survival (bRFS) rates at the median follow-up of 64 months according to the risk-group (a) and to the Gleason score (b)Back to article page